European marketing authorization of the Gilead Sciences drug, Sunlenca, provides a twice-yearly treatment option for HIV patients whose virus has become resistant to multiple therapies. An FDA decision for drug is expected in December.
One of the most important lessons learned in Africa—and throughout the Covid-19 pandemic—is that data is your biggest ally. We need data to tell us what’s going wrong and why. But most importantly, we need this information in real time.
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Although Descovy showed an advantageous side-effect profile, one doctor described Truvada as mostly well-tolerated, while another said switching to Descovy will depend on insurance coverage. Both expressed a desire for data in other vulnerable populations.
After disclosing the HIV statuses of up to 12,000 customers via a mailing, Aetna has been hit with a class-action lawsuit.
Also, HIMSS keynote strategy mocked, ACOs continues to be pummeled, and a new European initiative to speed up approval of innovative drugs.
Janssen Therapeutics is pushing patient engagement, with a touch of social media, for marketing HIV medication Prezcobix.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
An NIH study has shown that giving HIV drugs when patients are initially diagnosed with the disease is more effective than waiting for the white blood cell counts to drop.
When Dena Hughes learned about the Affordable Care Act’s passage, she rejoiced. Hughes, who is HIV positive, has struggled to find insurance coverage, because HIV is considered a pre-existing condition. But even under the new law, Hughes said her care providers had advised her not to enroll in the federal health care exchange yet. It […]
The House of Representatives passed the HIV Organ Policy Equity (HOPE) Act Nov. 12. Once signed into law, this would allow ‘positive to positive’ organ donations. According to the Human Rights Campaign: “Permitting organs from deceased, HIV-positive donors to be used for transplant to HIV-positive recipients has the potential to save 1,000 HIV-infected patients with […]
CHICAGO (Reuters) - A daily dose of powerful anti-HIV medicine helped cut the risk of infection with the AIDS virus by 49 percent in intravenous drug users in a Bangkok study that showed for the first time such a preventive step can work in this high-...
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
CHICAGO (Reuters) - An influential panel is calling for HIV screening for all Americans aged 15 to 65, regardless of whether they are considered to be at high risk, a change that may help lift some of the stigma associated with HIV testing. The new gu...
An undercurrent at most healthcare innovation conferences is “what’s to be done with the doctors?” It’s the same at this week’s World Health Care Congress in Washington, D.C. Dr. Vinod Khosla of Khosla Ventures told the audience on Tuesday that 50 percent of doctors are below average (it was supposed to be a critique but […]
The U.S. Preventive Services Task Force has released a draft recommendation that everyone 15 - 65 should get an AIDS test. People will hate this idea as much as the panel's mammogram recommendations, but for a different reason.
Gilead’s four-drug combo pill, taken just once a day, clearly is an innovation. But is it really 140 times more valuable than a generic approach?
An application for a higher dosage of an FDA-approved HIV drug from Janssen Pharmaceuticals has been turned down by the U.S. Food and Drug Administration, according to a company statement. The complete response letter was for an 800 milligram dose of Prezista, a protease inhibitor. The Titusville, New Jersey company, the Pharmaceutical Division of Johnson […]